REVOLADE 25mg price in UAE

Overview

Welcome to Dwaey, specifically on REVOLADE 25mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Eltrombopag (as olamine).
REVOLADE 25mg is available in the market in concentration 25mg/Tablet and in the form of Tablets/Film-coated.

GLAXO WELLCOME SA is the producer of REVOLADE 25mg and it is imported from SPAIN, The most popular alternatives of REVOLADE 25mg are listed downward .

Mode Of Action

Small-molecule thrombopoietin (TPO)-receptor agonist that interacts with human TPO receptor transmembrane domain of human TPO-receptor & initiates signaling cascades that induce proliferation & differentiation of megakaryocytes from bone marrow progenitor cells.

Indication

Adult chronic immune (idiopathic) thrombocytopenic purpura (ITP)
Hepatitis C Virus (HCV) related Thrombocytopenia.

Precaution

Not established for use in other thrombocytopenic conditions. Regularly monitor clinical haematology, platelet counts & serum liver test throughout therapy. Renal & hepatic impairment; hepatic disease. Thrombotic/thromboembolic complications. Increased risk of bleeding upon discontinuation of treatment. Bone marrow reticulin formation & risk of bone marrow fibrosis. Malignancies & progression of malignancies. Pregnancy & lactation. Childn <18 yr, elderly.

Side Effects

Insomnia; headache
paraesthesia; cataract
dry eye; nausea; GI & hepatobiliary disorders; rash
pruritus
alopecia; arthralgia
myalgia
muscle spasm
bone pain; fatigue
peripheral oedema; thromboembolic events.

Contra indication

Eltrombopag is contraindicated in patients with severe hepatic impairment and who are hypersensitive to any of its excipients.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased plasma Cmax & AUC of HMG-CoA reductase inhibitors. Caution w/ methotrexate, topotecan. Increased conc w/ fluvoxamine; decreased conc w/ rifampicin & lopinavir/ritonavir. Reduced absorption by antacids, dairy products & other products containing polyvalent cations (eg Fe, Ca, Mg, Al, Se, Zn). Reduced plasma AUC & Cmax w/ high-calorie & -fat meal. Monitor platelet counts when used in combination w/ lopinavir/ritonavir & other drugs for treatment of idiopathic thrombocytopenic purpura (ITP).